Publications by authors named "Dirk Waldschmidt"

Claim this Profile
P
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).
Manfred P Lutz, Nikolaus Ansorge, Gleb Barmashenko, Hans Bauer, Christof Burkart, Dirk Waldschmidt

Br J Cancer· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance training in cachectic pancreatic and lung cancer patients: randomised controlled trial.
Timo Niels, Lisa Stich, Stefanie Siebert, Sarah Man, Nico DeLazzari, Dirk Waldschmidt

BMJ Support Palliat Care· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Anthony B El-Khoueiry, Richard D Kim, William P Harris, Max W Sung, Dirk Waldschmidt

Hepatology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
Rainer Fietkau, Michael Ghadimi, Robert Grützmann, Uwe A Wittel, Lutz Jacobasch, Dirk Waldschmidt

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).
Conrad Rauber, Maria Paula Roberti, Maria Jgt Vehreschild, Anastasia Tsakmaklis, Christoph Springfeld, Dirk T Waldschmidt

BMJ Open· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Benefit of Structured Reporting Using the Liver Imaging Reporting and Data System (LI-RADS) in MRI in Patients at Risk for Hepatocellular Carcinoma.
Christian Nelles, Anton Wagner, Simon Lennartz, Robert Wawer Matos Reimer, Alexander Christian Bunck, Dirk Thomas Waldschmidt

Rofo· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy-relevant amplification in cholangiocarcinomas in Caucasian patients.
Su Ir Lyu, Patrick Sven Plum, Caroline Fretter, Adrian Georg Simon, Tillmann Bedau, Dirk Waldschmidt

Ther Adv Med Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
Thomas J Ettrich, Dominik P Modest, Marianne Sinn, Jana K Striefler, Bernhard Opitz, Dirk Waldschmidt

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence.
Su Ir Lyu, Caroline Fretter, Adrian Georg Simon, Sarah-Michele Spielmann, Alexander I Damanakis, Dirk Waldschmidt

Transl Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
Lena Weiss, Volker Heinemann, Laura E Fischer, Frank Gieseler, Thomas Hoehler, Dirk T Waldschmidt

Clin Transl Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
Danmei Zhang, C Benedikt Westphalen, Michael Quante, Dirk T Waldschmidt, Swantje Held

Eur J Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associating Appendicitis with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Novel Insight into an Unexpected Connection.
Christoph Roderburg, Dirk Waldschmidt, Catherine Leyh, Sarah Krieg, Andreas Krieg

J Clin Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.
Najib Ben Khaled, Max Seidensticker, Jens Ricke, Julia Mayerle, Bettina Oehrle, Dirk Waldschmidt

Future Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers.
Gabriel Allo, Ahu Damla Can, Roger Wahba, Nils Vogel, Tobias Goeser, Dirk Waldschmidt

Mol Clin Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC).
Florian Gebauer, Alexander Ioannis Damanakis, Felix Popp, Alexander Quaas, Fabian Kütting, Dirk Waldschmidt

BMC Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-Induced Protein With Multiple Tetratricopeptide Repeats 3 Is Associated With Response to Chemotherapy and Recurrence but Not With Survival.
Marie Christine Popp, Maximilian Klippstein, Philipp Lohneis, Thomas Kalinski, Jiahui Li, Dirk Waldschmidt

Pancreas· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma.
Katharina Leuchte, Elena Staib, Martin Thelen, Philipp Gödel, Axel Lechner, Dirk Waldschmidt

Cancer Immunol Immunother· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Volker Kunzmann, Jens T Siveke, Hana Algül, Eray Goekkurt, Gabriele Siegler, Dirk Waldschmidt

Lancet Gastroenterol Hepatol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structured Reporting of Solid and Cystic Pancreatic Lesions in CT and MRI: Consensus-Based Structured Report Templates of the German Society of Radiology (DRG).
Thorsten Persigehl, Matthias Baumhauer, Bettina Baeßler, Lukas Philipp Beyer, Marc Bludau, Dirk Thomas Waldschmidt

Rofo· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial].
C Benedikt Westphalen, Volker Heinemann, Hans Werner Tessen, Matthias Groschek, Heinz-Gert Hoeffkes, Dirk Waldschmidt

Z Gastroenterol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
C Benedikt Westphalen, Tobias Kukiolka, Benjamin Garlipp, Lars Hahn, Martin Fuchs, Dirk T Waldschmidt

BMC Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine.
Garry Ceccon, Michael Wollring, Anna Brunn, Martina Deckert, Dirk Waldschmidt

Case Rep Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proposal for a definition of "Oligometastatic disease in pancreatic cancer".
Alexander I Damanakis, Luisa Ostertag, Dirk Waldschmidt, Fabian Kütting, Alexander Quaas

BMC Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Alexander Quaas, Carina Heydt, Dirk Waldschmidt, Hakan Alakus, Thomas Zander

BMC Gastroenterol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Arndt Vogel, Stefan Kasper, Michael Bitzer, Andreas Block, Marianne Sinn, Dirk Waldschmidt

Eur J Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis